

Supplementary Material

Title: Prediction and associations of preterm birth and its subtypes with eicosanoid enzymatic pathways and inflammatory markers

Authors: Max T. Aung¹, Youfei Yu², Kelly K. Ferguson³, David E. Cantonwine⁴, Lixia Zeng⁵, Thomas F. McElrath⁴, Subramaniam Pennathur^{5,6,7}, Bhramar Mukherjee^{2,8}, John D. Meeker¹

¹Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI, US

²Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, US

³Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, US

⁴Division of Maternal and Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US

⁵Department of Internal Medicine-Nephrology, University of Michigan, Ann Arbor, MI, US

⁶Michigan Regional Comprehensive Metabolomics Resource Core, University of Michigan, Ann Arbor, MI, US

⁷Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, US

⁸Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, US

Plasma Lipid Parent Compounds	
α -linolenic acid	[α LA]
Arachidonic acid	[AA]
Docosahexaenoic acid	[DHA]
Eicosapentaenoic acid	[EPA]
Linoleic acid	[LA]

Plasma Eicosanoids: Cyclooxygenase Pathway	
13,14-dihydro-15-keto-prostaglandin D2	[3,14DHK-PGD2]
13,14-dihydro-15-keto-prostaglandin F2 α	[13,14DHK-PGF2 α]
15-deoxy-12,14-prostaglandin J2	[15DO12,14-PGJ2]
9-oxooctadeca-dienoic acid	[9-oxoODE]
Bicyclo-prostaglandin E1	[BCPGE1]
Bicycle-prostaglandin E2	[BCPGE2]
Prostaglandin A2	[PGA2]
Prostaglandin B2	[PGB2]
Prostaglandin D2	[PGD2]
Prostaglandin D3	[PGD3]
Prostaglandin E1	[PGE1]
Prostaglandin E2	[PGE2]
Prostaglandin E3	[PGE3]
Prostaglandin J2	[PGJ2]
Thromboxane B2	[TXB2]

Plasma Eicosanoids: Lipoxygenase Pathway	
Resolvin D1	[RVD1]
Resolvin D2	[RVD2]
Leukotriene B4	[LTB4]
Leukotriene C4 methyl-ester	[LTC4-ME]
Leukotriene D4	[LTD4]
Leukotriene E4	[LTE4]
13S-hydroxy-octadecadienoic acid	[13S-HODE]
5-hydroxy-eicosatetraenoic acid	[5-HETE]
8-hydroxy-eicosatetraenoic acid	[8-HETE]
12-hydroxy-eicosatetraenoic acid	[12-HETE]
15-hydroxy-eicosatetraenoic acid	[15-HETE]
13-oxooctadeca-dienoic acid	[13-oxoODE]
5-oxoeicosatetraenoic acid	[5-oxoETE]
12-oxoeicosatetraenoic acid	[12-oxoETE]
15-oxoeicosatetraenoic acid	[15-oxoETE]

Plasma Eicosanoids: Cytochrome P450 Pathway	
12,13-dihydroxy-octadecenoic acid	[12,13-DiHOME]
9,10-dihydroxy-octadecenoic acid	[9,10-DiHOME]
5,6-dihydroxy-eicosatrienoic acid	[5,6-DHET]
8,9-dihydroxy-eicosatrienoic acid	[8,9-DHET]
11,12-dihydroxy-eicosatrienoic acid	[11,12-DHET]
5,6-epoxy-eicosatrienoic acid	[5(6)-EET]
8,9-epoxy-eicosatrienoic acid	[8(9)-EET]
14,15-epoxy-eicosatrienoic acid	[14(15)-EET]
11,12-epoxy-eicosatrienoic acid	[11(12)-EET]
9,10-epoxy-octadecenoic acid	[9(10)-EpoME]
12,13-epoxy-octadecenoic acid	[12(13)-EpoME]
20-carboxy arachidonic acid	[CAA]
11-hydroxy-eicosatetraenoic acid	[11-HETE]
16-hydroxy-eicosatetraenoic acid	[16-HETE]
17-hydroxy-eicosatetraenoic acid	[17-HETE]
18-hydroxy-eicosatetraenoic acid	[18-HETE]
20-hydroxy-eicosatetraenoic acid	[20-HETE]
9S-hydroxy-octadecadienoic acid	[9S-HODE]

Plasma Inflammation Markers	
C-reactive protein	[CRP]
Interleukin-1 β	[IL1 β]
Interleukin-6	[IL6]
Interleukin-10	[IL10]
Tumor necrosis factor α	[TNF]


Plasma Protein Damage Markers	
3-nitrotyrosine	[NY]
<i>o,o'</i> -dityrosine	[DY]
3-chlorotyrosine	[CY]

Plasma Angiogenic Markers	
Placental growth factor	[PGF]
Soluble fms-like tyrosine kinase-1	[sFlt-1]


Urinary Oxidative Stress Markers	
8-hydroxydeoxyguanosine	[8-OHdG]
8-isoprostane	[8-IP]

Supplemental Figure 1. Schematic representation of individual biomarkers according to the media in which they were measured and the group they belong to.


A All Preterm and Control (Weighted)



B Spontaneous and Control (Weighted)



C Preterm Associated with Aberrant Placentation and Controls (Weighted)



Supplemental Figure 2. Weighted correlations among biomarkers. Correlations were calculated using inverse probability weighting for all preterm (A), spontaneous preterm (B), and placental preterm (C) to account for case-control sampling.

Supplemental Table 1. Log odds ratios (95% confidence interval) of preterm birth estimated using logistic regression and adaptive elastic-net

Biomarkers	All Preterm Birth		Spontaneous Preterm Birth		Placental Preterm Birth	
	Logistic Regression*	Adaptive Elastic-Net [†]	Logistic Regression*	Adaptive Elastic-Net [†]	Logistic Regression*	Adaptive Elastic-Net [†]
CRP	-0.18 (-0.54, 0.18)	NA	-0.25 (-0.69, 0.19)	NA	-0.02 (-0.57, 0.53)	NA
TNF-α	0.14 (-0.20, 0.48)	NA	-0.06 (-0.46, 0.34)	NA	0.42 (-0.10, 0.94)	NA
IL-10	0.44 (0.09, 0.79)	NA	0.20 (-0.20, 0.60)	NA	0.71 (0.22, 1.20)	NA
IL-6	0.36 (-0.001, 0.72)	NA	0.32 (-0.12, 0.75)	NA	0.26 (-0.25, 0.76)	NA
IL-1β	0.14 (-0.21, 0.48)	NA	0.15 (-0.27, 0.58)	NA	0.19 (-0.34, 0.71)	NA
DY	-0.07 (-0.42, 0.27)	NA	-0.01 (-0.45, 0.42)	NA	0.02 (-0.48, 0.52)	NA
CY	0.15 (-0.19, 0.50)	NA	0.21 (-0.22, 0.64)	NA	0.15 (-0.36, 0.67)	NA
NY	0.26 (-0.12, 0.64)	NA	0.20 (-0.27, 0.67)	NA	0.07 (-0.44, 0.58)	NA
sFlt-1	0.17 (-0.18, 0.52)	NA	0.18 (-0.26, 0.62)	NA	0.05 (-0.46, 0.55)	NA
PGF	-0.52 (-0.90, -0.14)	-0.24	-0.28 (-0.73, 0.16)	NA	-1.23 (-1.92, -0.54)	-0.15
8-OHdG	-0.23 (-0.60, 0.13)	NA	-0.48 (-0.96, 0.002)	NA	-0.11 (-0.59, 0.36)	NA
8-isoprostane	0.02 (-0.40, 0.43)	NA	0.47 (-0.27, 1.22)	NA	-0.25 (-0.78, 0.28)	NA
13,14DHK-PGD2	0.54 (0.14, 0.94)	NA	1.01 (0.49, 1.53)	NA	-0.15 (-0.63, 0.33)	NA
TXB2	0.16 (-0.18, 0.50)	NA	0.13 (-0.29, 0.54)	NA	0.18 (-0.32, 0.68)	NA
PGE2	0.28 (-0.09, 0.64)	NA	0.56 (0.05, 1.06)	NA	-0.09 (-0.59, 0.41)	NA
PGD2	0.21 (-0.14, 0.57)	NA	0.24 (-0.20, 0.67)	NA	0.22 (-0.31, 0.74)	NA
PGA2	0.25 (-0.10, 0.61)	NA	0.41 (-0.05, 0.87)	NA	0.12 (-0.37, 0.61)	NA
15DO12,14-PGJ2	0.41 (0.06, 0.77)	0.23	0.76 (0.27, 1.26)	0.11	-0.12 (-0.60, 0.36)	NA
PGD3	0.19 (-0.17, 0.55)	NA	0.42 (-0.04, 0.89)	NA	-0.04 (-0.54, 0.46)	NA
PGE3	0.01 (-0.34, 0.37)	NA	0.07 (-0.38, 0.52)	NA	-0.02 (-0.53, 0.50)	NA
PGJ2	-0.15 (-0.51, 0.20)	NA	-0.48 (-0.93, -0.02)	NA	0.23 (-0.37, 0.83)	NA
BCPGE1	0 (-0.34, 0.34)	NA	0.23 (-0.18, 0.64)	NA	-0.62 (-1.23, -0.01)	NA
BCPGE2	0.06 (-0.28, 0.40)	NA	0.23 (-0.18, 0.65)	NA	-0.55 (-1.12, 0.03)	NA
13,14DHK-PGF2a*	0.19 (-0.15, 0.54)	NA	0.61 (0.18, 1.05)	NA	-0.49 (-1.07, 0.09)	NA
PGB2	0.30 (-0.13, 0.72)	NA	0.65 (0.07, 1.23)	NA	-0.10 (-0.56, 0.36)	NA
9-oxoODE	-0.36 (-0.70, -0.02)	NA	-0.65 (-1.06, -0.25)	NA	0.30 (-0.33, 0.93)	NA
PGE1	0.16 (-0.19, 0.51)	NA	0.34 (-0.11, 0.79)	NA	-0.23 (-0.71, 0.26)	NA
12,13-DiHOME	0.32 (-0.02, 0.66)	NA	0.46 (0.05, 0.87)	NA	0.14 (-0.35, 0.64)	NA
9,10-DiHOME	0.37 (-0.01, 0.74)	NA	0.65 (0.15, 1.16)	NA	-0.06 (-0.58, 0.45)	NA
8,9-DHET	0.49 (0.06, 0.91)	NA	0.78 (0.18, 1.37)	NA	-0.001 (-0.51, 0.51)	NA
8(9)-EET	0.37 (-0.01, 0.74)	NA	0.65 (0.15, 1.16)	NA	-0.06 (-0.58, 0.45)	NA
14(15)-EET	-0.09 (-0.43, 0.25)	NA	-0.26 (-0.65, 0.13)	NA	0.49 (-0.18, 1.16)	NA

11(12)-EET	0.48 (0.06, 0.90)	NA	0.77 (0.18, 1.35)	NA	-0.002 (-0.51, 0.50)	NA
5(6)-EET	-0.37 (-0.72, -0.01)	-0.10	-0.63 (-1.08, -0.18)	-0.16	0.30 (-0.26, 0.86)	NA
12(13)-EpoME	-0.36 (-0.70, -0.02)	NA	-0.65 (-1.06, -0.25)	NA	0.30 (-0.33, 0.93)	NA
9(10)-EpoME	0.42 (0.04, 0.79)	NA	0.91 (0.37, 1.46)	NA	-0.20 (-0.70, 0.31)	NA
CAA	0.09 (-0.25, 0.43)	NA	0.25 (-0.19, 0.69)	NA	-0.09 (-0.57, 0.39)	NA
20-HETE	-0.13 (-0.47, 0.22)	NA	-0.35 (-0.77, 0.07)	NA	0.49 (-0.13, 1.11)	NA
11-HETE	-0.07 (-0.41, 0.27)	NA	-0.36 (-0.78, 0.05)	NA	0.52 (-0.06, 1.10)	NA
16-HETE	0.04 (-0.31, 0.39)	NA	0.10 (-0.35, 0.55)	NA	0.01 (-0.50, 0.51)	NA
17-HETE	-0.02 (-0.36, 0.32)	NA	0.19 (-0.24, 0.62)	NA	-0.29 (-0.81, 0.23)	NA
18-HETE	-0.002 (-0.34, 0.34)	NA	0.33 (-0.11, 0.76)	NA	-0.30 (-0.82, 0.23)	NA
11,12-DHET	0.5 (0.15, 0.86)	NA	0.96 (0.52, 1.39)	NA	-0.78 (-1.58, 0.03)	NA
5,6-DHET	-0.10 (-0.44, 0.25)	NA	-0.31 (-0.74, 0.12)	NA	0.29 (-0.24, 0.81)	NA
9S-HODE	0.14 (-0.20, 0.48)	NA	0.27 (-0.16, 0.70)	NA	0.03 (-0.48, 0.55)	NA
RVD2	0.21 (-0.12, 0.55)	NA	0.46 (0.05, 0.87)	NA	-0.39 (-0.96, 0.17)	NA
RVD1	0.65 (0.25, 1.05)	NA	0.98 (0.47, 1.49)	0.02	0.14 (-0.44, 0.73)	NA
5-HETE	0.34 (-0.002, 0.69)	NA	0.69 (0.25, 1.13)	NA	-0.16 (-0.66, 0.34)	NA
LTD4	0.38 (0.03, 0.72)	NA	0.88 (0.44, 1.32)	NA	-0.80 (-1.57, -0.03)	NA
LTE4	0.38 (-0.02, 0.89)	NA	0.67 (0.17, 1.17)	NA	-0.18 (-0.86, 0.50)	NA
LTC4-ME	0.30 (-0.07, 0.66)	NA	0.53 (0.04, 1.03)	NA	-0.10 (-0.56, 0.36)	NA
13S-HODE	0.28 (-0.08, 0.64)	NA	0.45 (-0.01, 0.91)	NA	0.33 (-0.22, 0.88)	NA
13-oxoODE	-0.25 (-0.61, 0.10)	NA	-0.39 (-0.83, 0.05)	NA	0.21 (-0.34, 0.76)	NA
5-oxoETE	0.28 (-0.08, 0.64)	NA	0.57 (0.10, 1.05)	0.16	-0.16 (-0.68, 0.37)	NA
15-oxoETE	0.17 (-0.19, 0.52)	NA	0.12 (-0.33, 0.57)	NA	0.26 (-0.27, 0.79)	NA
12-oxoETE	0.27 (-0.09, 0.63)	NA	0.53 (0.06, 1.00)	NA	-0.20 (-0.72, 0.32)	NA
15-HETE	0.39 (0.02, 0.77)	NA	0.67 (0.19, 1.15)	NA	-0.002 (-0.51, 0.50)	NA
12-HETE	0.37 (0.01, 0.74)	NA	0.51 (0.04, 0.98)	NA	0.12 (-0.37, 0.62)	NA
8-HETE	0.29 (-0.09, 0.66)	NA	0.49 (-0.04, 1.01)	NA	-0.01 (-0.49, 0.47)	NA
LTB4	-0.31 (-0.67, 0.04)	-0.13	0.05 (-0.37, 0.47)	NA	-0.83 (-1.42, -0.23)	-0.10
DHA	0.36 (0, 0.73)	NA	0.84 (0.35, 1.34)	NA	-0.44 (-1.04, 0.16)	NA
EPA	0.43 (0.06, 0.79)	NA	0.87 (0.37, 1.37)	NA	-0.29 (-0.84, 0.25)	NA
AA	0.29 (-0.06, 0.64)	NA	0.56 (0.10, 1.02)	NA	-0.08 (-0.59, 0.42)	NA
αLA	0.50 (0.11, 0.88)	NA	0.89 (0.33, 1.44)	NA	0.07 (-0.47, 0.61)	NA
LA	0.36 (-0.003, 0.72)	0.26	0.54 (0.07, 1.00)	NA	0.20 (-0.34, 0.74)	NA

*Log odds ratios were estimated by fitting logistic regression on covariates and individual biomarkers (*Model 1*)

†Only point estimates are reported for the log odds ratios estimated by adaptive elastic-net. Zero coefficients are recorded as NA.